Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives

doi:10.3748/wjg.v16.i45.5732

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 45

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3583)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

310

HTML

2753

Figures (1-2)

270

Tables (1-5)

250

Sum=3583

Dec 7, 2010 (publication date) through Mar 10, 2025

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 7, 2010; 16(45): 5732-5738
Published online Dec 7, 2010. doi: 10.3748/wjg.v16.i45.5732

Table 1 Characteristics of patients, relatives and control group subjects n (%)

	CD (n = 64)	CD relatives (n = 25)	UC (n = 63)	UC relatives (n = 28)	Control (n = 34)
Sex
Male	28 (43.8)	9 (36.0)	32 (50.8)	11 (39.3)	15 (44.1)
Female	36 (56.2)	16 (64.0)	31 (49.2)	17 (60.7)	19 (55.9)
Age (yr, mean ± SD)	37.93 ± 14.01	32.12 ± 14.31	38.74 ± 13.13	35.35 ± 17.07	38.58 ± 15.09
Disease duration (yr, mean ± SD)	4.37 ± 3.61		4.03 ± 3.66
Disease location (CD)
Colon	2 (3.1)
Ileum	26 (40.6)
Ileocolonic	36 (56.3)
Disease location (UC)
Proctitis			9 (14.3)
Distal involvement			24 (38.1)
Left colon invol			9 (14.3)
Diffuse			2 (3.2)
Pancolitis			19 (30.2)
Disease type (CD)
Stricturing	7 (10.9)
Penetrating	6 (9.4)
Inflammatory	51 (79.7)
Medications (for CD and UC)
No medication	5 (7.8)		5 (7.9)
5-ASA	57 (89.06)		57 (90.4)
Steroids	5 (7.8)		5 (7.9)
AZA	13 (20.3)		8 (12.6)
Antibiotics	1 (1.6)		3 (4.7)

CD: Crohn’s disease; UC: Ulcerative colitis; 5-ASA: 5-aminosalicylic acid; AZA: Azathioprine.

Table 2 Pancreatic antibody and anti-Saccharomyces cerevisiae positivity results in study groups n (%)

	CD (n = 64)	UC (n = 63)	CD relatives (n = 25)	UC relatives (n = 28)	Control (n = 34)
PAB	9 (14.1)	5 (7.9)	0 (0)	0 (0)	0 (0)
ASCA	37 (57.8)	13 (20.6)	9 (36)	5 (17.9)	6 (17.6)

CD: Crohn’s disease; UC: Ulcerative colitis; PAB: Anti-pancreatic antibody; ASCA: Anti-Saccharomyces cerevisiae.

Table 3 Positivity rates of pancreatic antibody according to Vienna classification

		A1 (n = 43, PAB = 7, 16.27%)				A2 (n = 21, PAB = 2, 9.52%)
		B1 (n = 31, PAB = 5, 16.12%)	B2 (n = 6, PAB = 1, 16.66%)	B3 (n = 6, PAB = 1, 16.66%)		B1 (n = 20, PAB = 2, 10%)	B2 (n = 1, PAB = 0, 0%)	B3 (n = 0, PAB = 0, 0%)
L1 (n = 26, 3.84%)	A1 (n = 18, PAB = 1, 5.55%)	n = 15, PAB = 1, 6.66%	n = 0, PAB = 0, 0%	n = 3, PAB = 0, 0%	A2 (n = 8, PAB = 0, 0%)	n = 7, PAB = 0, 0%	n = 1, PAB = 0, 0%	n = 0, PAB = 0, 0%
L2 (n = 2, 0%)	A1 (n = 1, PAB = 0, 0%)	n = 1, PAB = 0, 0%	n = 0, PAB = 0, 0%	n = 0, PAB = 0, 0%	A2 (n = 1, PAB = 0, 0%)	n = 1, PAB = 0, 0%	n = 0, PAB = 0, 0%	n = 0, PAB = 0, 0%
L3 (n = 36, 22.22%)	A1 (n = 24, PAB = 6, 25%)	n = 15, PAB = 4, 25%	n = 6, PAB = 1, 16.66%	n = 3, PAB = 1, 33.33%	A2 (n = 12, PAB = 2, 16.66%)	n = 12, PAB = 2, 16.66%	n = 0, PAB = 0, 0%	n = 0, PAB = 0, 0%

A1: Disease onset age < 40 yr; A2: Disease onset age ≥ 40 yr; B1: Inflammatory type; B2: Stricturizing type; B3: Fistulizing type; L1: Ileal involvement; L2: Colonic involvement; L3: Ileocolonic involvement. PAB: Pancreatic antibody.

Table 4 Positivity rates of anti-Saccharomyces cerevisiae according to Vienna classification

		A1 (n = 43, ASCA = 27, 62.79%)				A2 (n = 21, ASCA = 10, 47.61%)
		B1 (n = 31, ASCA = 18, 58.06%)	B2 (n = 6, ASCA = 3, 50%)	B3 (n = 6, ASCA = 6, 100%)		B1 (n = 20, ASCA = 9, 45%)	B2 (n = 1, ASCA = 1, 100%)	B3 (n = 0, ASCA = 0, 0%)
L1 (18/26, 69.23%)	A1 (n = 18, ASCA = 13, 72.22%)	n = 15, ASCA = 10, 66.66%	n = 0, ASCA = 0, 0%	n = 3, ASCA = 3, 100%	A2 (n = 8, ASCA = 5, 62.5%)	n = 7, ASCA = 4, 57.14%	n = 1, ASCA = 1, 100%	n = 0, ASCA = 0, 0%
L2 (0/2, 0%)	A1 (n = 1, ASCA = 0, 0%)	n = 1, ASCA = 0, 0%	n = 0, ASCA = 0, 0%	n = 0, ASCA = 0, 0%	A2 (n = 1, ASCA = 0, 0%)	n = 1, ASCA = 0, 0%	n = 0, ASCA = 0, 0%	n = 0, ASCA = 0, 0%
L3 (19/36, 52.77%)	A1 (n = 24, ASCA = 14, 58.33%)	n = 15, ASCA = 8, 53.33%	n = 6, ASCA = 3, 50%	n = 3, ASCA = 3, 100%	A2 (n = 12, ASCA = 5, 41.66%)	n = 12, ASCA = 5, 41.66%	n = 0, ASCA = 0, 0%	n = 0, ASCA = 0, 0%

Table 5 Pancreatic antibody and anti-Saccharomyces cerevisiae positivity according to Crohn’s disease activity index n (%)

Disease activity according to CDAI	PAB		ASCA		Total
Disease activity according to CDAI	Negative	Positive	Negative	Positive
Mild (< 150 points)	49 (84.5)	9 (15.5)	27 (46.6)	31 (53.4)	58 (100)
Moderate (150-450 points)	5 (100)	0 (0)	0 (0)	5 (100)	5 (100)
Severe (> 450 points)	1 (100)	0 (0)	0 (0)	1 (100)	1 (100)
Total	55	9	27	37	64

CDAI: Crohn’s disease activity index; PAB: Pancreatic antibody; ASCA: Anti-Saccharomyces cerevisiae.

Citation: Demirsoy H, Ozdil K, Ersoy O, Kesici B, Karaca C, Alkim C, Akbayir N, Erdem LK, Onuk MD, Beyzadeoglu HT. Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives. World J Gastroenterol 2010; 16(45): 5732-5738
URL: https://www.wjgnet.com/1007-9327/full/v16/i45/5732.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i45.5732